Impact of Inherited Prothrombotic Disorders on the Long-Term Clinical Outcome of Percutaneous Transluminal Angioplasty in Patients with Diabetes
Language English Country United States Media print-electronic
Document type Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
26247037
PubMed Central
PMC4515498
DOI
10.1155/2015/369758
Knihovny.cz E-resources
- MeSH
- Angioplasty adverse effects MeSH
- Leg blood supply MeSH
- Point Mutation * MeSH
- Diabetic Angiopathies etiology physiopathology therapy MeSH
- Factor V analysis genetics MeSH
- Genetic Association Studies MeSH
- Ischemia epidemiology etiology prevention & control MeSH
- Middle Aged MeSH
- Humans MeSH
- Methylenetetrahydrofolate Reductase (NADPH2) blood genetics MeSH
- Arm blood supply MeSH
- Prevalence MeSH
- Prothrombin analysis genetics MeSH
- Cross-Sectional Studies MeSH
- Recurrence MeSH
- Aged MeSH
- Amino Acid Substitution MeSH
- Thrombophilia blood complications genetics physiopathology MeSH
- Thrombosis complications etiology physiopathology therapy MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Controlled Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- factor V Leiden MeSH Browser
- Factor V MeSH
- Methylenetetrahydrofolate Reductase (NADPH2) MeSH
- MTHFR protein, human MeSH Browser
- Prothrombin MeSH
The aim of our study was to analyse inherited thrombotic disorders that influence the long-term outcome of PTA. Methods. Diabetic patients with peripheral arterial disease (PAD) treated by PTA in our centre between 2008 and 2011 were included in the study. Patients were divided into unsuccessful PTA group (75 patients), successful PTA group (58 patients), and control group (65 patients, with diabetes but no PAD). Diagnosis of inherited thrombotic disorders included mutation in factor V (Leiden), factor II (prothrombin), and mutation in genes for methylenetetrahydrofolate reductase-MTHFR (C677T and A1298C). Results. The genotypic frequency of Leiden allele G1691A was significantly associated with a risk of unsuccessful PTA in comparison with successful PTA group and control group (OR 8.8 (1.1-70.6), p = 0.041, and OR 9.8 (1.2-79.2), p = 0.032, resp.). However, we only observed a trend for the association of the prothrombin allele G20210A and risk of PTA failure. The frequencies of alleles of MTHFR 677 or 1298 did not differ significantly among the groups. Conclusion. Our study showed higher frequency of heterozygous form of Leiden mutation in diabetic patients with unsuccessful outcome of PTA in comparison with patients with successful PTA and diabetic patients without PAD.
See more in PubMed
Kyrle P. A., Rosendaal F. R., Eichinger S. Risk assessment for recurrent venous thrombosis. The Lancet. 2010;376(9757):2032–2039. doi: 10.1016/S0140-6736(10)60962-2. PubMed DOI
Reitsma P. H. Genetics in thrombophilia. An update. Hämostaseologie. 2015;35(1):47–51. doi: 10.5482/hamo-14-11-0062. PubMed DOI
Mandegar M. H., Saidi B., Roshanali F. Extensive arterial thrombosis in a patient with factor V leiden mutation. Interactive Cardiovascular and Thoracic Surgery. 2010;11(1):127–129. doi: 10.1510/icvts.2010.232710. PubMed DOI
Mishra M. N., Kalra R., Rohatgi S. Clinical profile, common thrombophilia markers and risk factors in 85 young Indian patients with arterial thrombosis. Sao Paulo Medical Journal. 2013;131(6):384–388. doi: 10.1590/1516-3180.2013.1316369. PubMed DOI PMC
Yokus O., Albayrak M., Balcik O. S., et al. Risk factors for thrombophilia in young adults presenting with thrombosis. International Journal of Hematology. 2009;90(5):583–590. doi: 10.1007/s12185-009-0447-6. PubMed DOI
Tepe G., Laird J., Schneider P., et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502. doi: 10.1161/circulationaha.114.011004. PubMed DOI PMC
Peregrin J. H., Kožnar B., Kováč J., et al. PTA of infrapopliteal arteries: long-term clinical follow-up and analysis of factors influencing clinical outcome. CardioVascular and Interventional Radiology. 2010;33(4):720–725. doi: 10.1007/s00270-010-9881-3. PubMed DOI
Grant A. G., White C. J., Collins T. J., Jenkins J. S., Reilly J. P., Ramee S. R. Infrapopliteal drug-eluting stents for chronic limb ischemia. Catheterization and Cardiovascular Interventions. 2008;71(1):108–111. doi: 10.1002/ccd.21367. PubMed DOI
Reny J.-L., Alhenc-Gelas M., Fontana P., et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. Journal of Thrombosis and Haemostasis. 2004;2(8):1334–1340. doi: 10.1111/j.1538-7836.2004.00809.x. PubMed DOI
Sartori M., Conti E., Favaretto E., Frascaro M., Legnani C., Palareti G. Thrombotic risk factors and cardiovascular events after endovascular intervention for peripheral arterial disease. European Journal of Vascular and Endovascular Surgery. 2011;42(6):817–823. doi: 10.1016/j.ejvs.2011.08.016. PubMed DOI
Bém R., Jirkovská A., Dubský M., et al. Pětiletá incidence a rizikové faktory Charcotovy neuroosteoartropatie po kombinované transplantaci pankreatu a ledviny a izolované transplantaci pankreatu. Diabetologie, Metabolismus, Endokrinologie Výziva. 2010;13(supplement 1):p. 21.
Adams R. L. C., Bird R. J. Review article: coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants. Nephrology. 2009;14(5):462–470. doi: 10.1111/j.1440-1797.2009.01128.x. PubMed DOI
Dubský M., Jirkovská A., Bém R., et al. Comparison of healing of ischaemic diabetic foot ulcers after stem cell therapy or percutaneous transluminal angioplasty (Abstract) Diabetologia. 2010;53(supplement 1):p. S57.
Favaloro E. J., McDonald D., Lippi G. Laboratory investigation of thrombophilia: the good, the bad, and the ugly. Seminars in Thrombosis and Hemostasis. 2009;35(7):695–710. doi: 10.1055/s-0029-1242723. PubMed DOI
Kadauke S., Khor B., Van Cott E. M. Activated protein C resistance testing for factor V Leiden. The American Journal of Hematology. 2014;89(12):1147–1150. doi: 10.1002/ajh.23867. PubMed DOI
MacCallum P., Bowles L., Keeling D. Diagnosis and management of heritable thrombophilias. British Medical Journal. 2014;349 doi: 10.1136/bmj.g4387.g4387 PubMed DOI
Jadaon M. M. Epidemiology of prothrombin G20210A mutation in the Mediterranean region. Mediterranean Journal of Hematology and Infectious Diseases. 2011;3(1) doi: 10.4084/mjhid.2011.054.e2011054 PubMed DOI PMC
Cattaneo M. Hyperhomocysteinemia and venous thromboembolism. Seminars in Thrombosis and Hemostasis. 2006;32(7):716–723. doi: 10.1055/s-2006-951456. PubMed DOI
Zhang P., Gao X., Zhang Y., et al. Association between MTHFR C677T polymorphism and venous thromboembolism risk in the chinese population: a meta-analysis of 24 case-controlled studies. Angiology. 2015;66(5):422–432. doi: 10.1177/0003319714546368. PubMed DOI
Wald D. S., Morris J. K., Wald N. J. Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PLoS ONE. 2011;6(2) doi: 10.1371/journal.pone.0016473.e16473 PubMed DOI PMC
Norgren L., Hiatt W., Dormandy J., Nehler M., Harris K., Fowkes F. Inter-society consensus for the management of peripheral arterial disease (TASC II) European Journal of Vascular and Endovascular Surgery. 2007;33(supplement 1):S1–S75. doi: 10.1016/j.ejvs.2006.09.024. PubMed DOI
Schaper N. C. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/Metabolism Research and Reviews. 2004;20(1):S90–S95. doi: 10.1002/dmrr.464. PubMed DOI
Dubský M., Jirkovská A., Bém R., et al. Acellulární porcinní dermis v lokální léčbě syndromu diabetické nohy. Praktické lékařství. 2010;90(6):342–346.
Zuojun H., Lingyu H., Wei H., et al. Interference of IP-10 expression inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in carotid artery: a new insight in the prevention of restenosis. Cell Biochemistry and Biophysics. 2012;62(1):125–135. doi: 10.1007/s12013-011-9270-9. PubMed DOI
Dzau V. J., Braun-Dullaeus R. C., Sedding D. G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nature Medicine. 2002;8(11):1249–1256. doi: 10.1038/nm1102-1249. PubMed DOI
Bayes-Genis A., Conover C. A., Schwartz R. S. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circulation Research. 2000;86(2):125–130. doi: 10.1161/01.res.86.2.125. PubMed DOI
Hanifi-Moghaddam P., Schloot N. C., Kappler S., Seissler J., Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes. 2003;52(5):1137–1142. doi: 10.2337/diabetes.52.5.1137. PubMed DOI
Gemmati D., Serino M. L., Trivellato C., Fiorini S., Scapoli G. L. C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients. Haematologica. 1999;84(9):824–828. PubMed
Sampram E. S. K., Lindblad B., Dahlback B. Activated protein C resistance in patients with peripheral vascular disease. Journal of Vascular Surgery. 1998;28(4):624–629. doi: 10.1016/S0741-5214(98)70086-2. PubMed DOI
